AmyriAD
2 known investors
AmyriAD Therapeutics is developing Ismidenon (formerly AD101), a once-daily oral small molecule therapy intended to improve cognition and function in patients with Alzheimer's disease. The drug uses a multi-modal approach to acetylcholine stimulation and is in preparation for a Phase 2/3 registration trial in the US.
BiotechLongevity
Investors · 2
Frequently asked questions
- What does AmyriAD do?
- AmyriAD Therapeutics is developing Ismidenon (formerly AD101), a once-daily oral small molecule therapy intended to improve cognition and function in patients with Alzheimer's disease. The drug uses a multi-modal approach to acetylcholine stimulation and is in preparation for a Phase 2/3 registration trial in the US.
- Who are AmyriAD's investors?
- AmyriAD's investors include Elevat3 Capital, What If Ventures.